Accelerate your path to clinical trials with rapid toxicology material supply

Are you looking to expedite your drug development process? Lonza's rapid tox offering is designed to accelerate your biotherapeutic development timelines. By providing toxicology material for your mAb and bispecific in as little as 2.5 months*, you could advance your development program faster and with confidence.

*Indicative non-binding timelines from DNA transfection

Explore expert insights highlighting the benefits of Lonza’s rapid tox offering:

• Breaking the toxicology bottleneck for IND submissions:
  The article highlights how innovative strategies and emerging technologies are transforming toxicology material delivery into a key enabler of accelerated drug development timelines.
  Read the article
• Accelerating the path to clinical filing applications:
  Lonza’s ability to provide tox material supply to initiate toxicology studies early, already enables customers to remove bottlenecks on the road to FIH for more traditional biologics and will continue to be an important asset.
  Read the article
• Rapid delivery of toxicological study material:
  This short webinar explores key strategies and technologies that enable the rapid delivery of toxicology material. We introduce our newly developed offerings, designed to accelerate tox material generation by up to 50% and advance the timeline for toxicology studies.
  Watch on-demand